1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015" provides an overview of Neisseria meningitidis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Figures 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Neisseria meningitidis Infections Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profile Snapshots 32
Appendix 186
Abbreviations 186
Definitions 186
Research Methodology 187
Secondary Research 187
About GlobalData 188
Contact Us 188
Disclaimer 188
Source 189

List of Figures
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Region, 2015* 6
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neisseria meningitidis Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Neisseria meningitidis Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Neisseria meningitidis Infections Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Neisseria meningitidis Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Neisseria meningitidis Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 16
Neisseria meningitidis Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Neisseria meningitidis Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19
Neisseria meningitidis Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Neisseria meningitidis Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Neisseria meningitidis Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 27
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31

List of Figures
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neisseria meningitidis Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Neisseria meningitidis Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Neisseria meningitidis Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Neisseria meningitidis Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Neisseria meningitidis Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 15
Neisseria meningitidis Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Neisseria meningitidis Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Neisseria meningitidis Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19
Neisseria meningitidis Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Neisseria meningitidis Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Neisseria meningitidis Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Neisseria meningitidis Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 27
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Neisseria meningitidis Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
GlobalData Methodology 187

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Neisseria Meningitidis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

Neisseria Meningitidis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • $ 2000
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Report, “Neisseria Meningitidis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...

 Neisseria Meningitidis Infections-Pipeline Insights, 2017

Neisseria Meningitidis Infections-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ Neisseria Meningitidis Infections-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Neisseria Meningitidis ...

 Meningococcal Meningitis-Pipeline Insights, 2017

Meningococcal Meningitis-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ Meningococcal Meningitis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Meningococcal Meningitis. ...


Download Unlimited Documents from Trusted Public Sources

Meningococcal Statistics and Arthritis Statistics in the Netherlands

  • March 2017
    6 pages
  • Meningococcal  

    Arthritis  

  • Netherlands  

View report >

Infectious Disease Statistics in the US

  • March 2017
    36 pages
  • Infectious Dise...  

  • United States  

    North America  

View report >

Tuberculosis Statistics

  • March 2017
    200 pages
  • Infectious Dise...  

    Tuberculosis  

  • United States  

    North America  

    Europe  

View report >

Related Market Segments :

Meningococcal
Infectious Disease
Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.